Delusional parasitosis and the dopamine transporter. A new insight of etiology?

Medical Hypotheses

Volumn 68, Issue 6, 2007, Pages 1351-1358

  Huber, M ^a   Kirchler, E ^a   Karner, M ^a   Pycha, R ^a  

^a BRUNECK HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ATYPICAL ANTIPSYCHOTIC AGENT; BLEOMYCIN; BROMIDE; CAPTOPRIL; CLONIDINE; COCAINE; CORTICOSTERONE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; HALOPERIDOL; KETOCONAZOLE; MEFLOQUINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; NORADRENALIN; NORADRENALIN TRANSPORTER; OLANZAPINE; PEMOLINE; PHENELZINE; PIMOZIDE; PSYCHOSTIMULANT AGENT; RISPERIDONE;

ALCOHOLISM; ARTICLE; BRAIN; BRAIN BLOOD FLOW; BRAIN INJURY; CEREBROVASCULAR DISEASE; COCAINE DEPENDENCE; DEGENERATIVE DISEASE; DELUSIONAL DISORDER; DELUSIONAL PARASITOSIS; DEPRESSION; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; DRUG CHOICE; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; HYPERURICEMIA; IMMUNOHISTOCHEMISTRY; INFESTATION; IRON DEFICIENCY; LIGAND BINDING; MENTAL DISEASE; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARANOID SCHIZOPHRENIA; PARASITOSIS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANCE ABUSE; TRAUMATIC BRAIN INJURY;

COCAINE; CORPUS STRIATUM; DELUSIONS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; METHYLPHENIDATE; MODELS, PSYCHOLOGICAL; PARASITIC DISEASES; PEMOLINE; PROTEIN BINDING;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33947709589     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.07.061     Document Type: Article

References (76)

1. Marneros A., Deister A., and Rohde A. Delusional parasitosis. A comparative study to late-onset schizophrenia and organic mental disorders due to cerebral arteriosclerosis. Psychopathology 21 6 (1988) 267-274
2. Trabert W. 100 years of delusional parasitosis. Meta-analysis of 1223 case reports. Psychopathology 28 5 (1995) 238-246
3. Amancio E.J., Peluso C.M., Santos A.C., et al. Ekbom's syndrome and spasmodic torticollis: case report. Arq Neuro-Psiquiat 60 1 (2002) 155-158
4. Freudenmann R.W. Delusions of parasitosis: an up-to-date review. Fortschr Neurol Psychiat 70 10 (2002) 531-541
5. Slaughter J.R., Zanol K., Rezwani H., and Flax J. Psychogenic parasitosis. A case series and literature review. Psychosomatics 39 6 (1998) 491-500
6. Schenk J.O. The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate. Prog Drug Res 59 (2002) 111-131
7. Bannon M.J. The dopamine transporter: role in neurotoxiticity and human disease. Toxicol Appl Pharm 204 3 (2005) 355-360
8. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Therapeut 91 1 (2001) 35-62
9. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., and Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine. Proc Natl Acad Sci USA 95 7 (1998) 4029-4034
10. Melikian H.E., and Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 19 18 (1999) 7699-7710
11. Elpern D.J. Cocaine abuse and delusions of parasitosis. Cutis 42 4 (1988) 273-274
12. Krauseneck T., and Soyka M. Delusional parasitosis associated with pemoline. Psychopathology 38 2 (2005) 103-104
13. Gross-Tsur V., Joseph A., and Shalev R.S. Hallucinations during methylphenidate therapy. Neurology 63 4 (2004) 753-754
14. Marschall M.A., Dolezal R.F., Cohen M., and Marschall S.F. Chronic wounds and delusions of parasitosis in the drug abuser. Plast Reconstr Surg 88 2 (1991) 328-330
15. Volkow N.D., Ding Y., Fowler J.S., et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiat 52 6 (1995) 456-463
16. Volkow N.D., Wang G.J., Fowler J.S., et al. Dopamine transporters occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiat 155 10 (1998) 1325-1331
17. Molina V.A., and Orsingher O.A. Effects of Mg-pemoline on the central catecholaminergic system. Arch Int Pharmacodyn Ther 251 1 (1981) 66-79
18. Kahlig K.M., and Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 479 1-3 (2003) 153-158
19. Elliott J.M., and Beveridge T.J. Psychostimulants and monoamine transporters: upsetting the balance. Curr Opin Pharmacol 5 1 (2005) 94-100
20. Geng Y., Shi G.H., Jiang Y., Xu L.X., Hu X.Y., and Shao Y.Q. Investigating the role of 99mTC-Trodat-1 SPECT imaging in idiopathic Parkinson's disease. J Zhejiang Univ Schi B 6 1 (2005) 22-27
21. Lorberboym M., Djaldetti R., Melamed E., Sadeh M., and Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 45 10 (2004) 1688-1693
22. EL Fakhri G., Habert M.O., Maksud P., et al. Quantitative simultaneous (99)TC-ECD/(123)I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 33 1 (2006) 87-92
23. Suzuki M., Desmond T.J., Albin R.L., and Frey K.A. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse 41 4 (2001) 329-336
24. Fujita M., Shimada S., Tohyama M., and Nishimura T. Visualization of ischemic insult in caudate Putamen with beta CIT. J Nucl Med 37 7 (1996) 1214-1218
25. Meng S.Z., Ohyu J., Itoh M., and Takashima S. Dopamine transporter and nitric oxide synthase in hypoxic-ischemic brain. Pediatr Neurol 22 2 (2000) 115-121
26. Repo E., Kuikka J.T., Bergstrom K.A., Karhu J., Hiltunen J., and Tiihonen J. Dopamine transporter and D2-recptor density in late-onset alcoholism. Psychopharmacology 147 3 (1999) 314-318
27. Robinson D.L., Volz T.J., Schenk J.O., and Wightman R.M. Acute ethanol decreases dopamine transporter velocity in rat striatum: in vivo and in vitro electrochemical measurements. Alcohol Clin Exp Res 29 5 (2005) 746-755
28. Wagner A.K., Sokoloski J.E., Ren D., et al. Controlled cortical impact injury affects dopaminergic transmission in the rat striatum. J Neurochem 95 2 (2005) 457-465
29. Wagner A.K., Chen X., Kline A.E., Li Y., Zafonte R.D., and Dixon C.E. Gender and environmental enrichment impact dopamine transporter expression after experimental traumatic brain injury. Exp Neurol 195 2 (2005) 475-483
30. Wong D.F., Harris J.C., Naidu S., et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci USA 93 11 (1996) 5539-5543
31. Wang G.J., Chang L., Volkow N.D., et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127 11 (2004) 2452-2458
32. Erikson K.M., Jones B.C., and Beard J.L. Iron deficiency alters dopamine transporter functioning in rat striatum. J Nutr 130 11 (2000) 2831-2837
33. Laakso A., Bergmann J., Haaparanta M., et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52 1-2 (2001) 115-120
34. Mateos J.J., Lomena F., Parellada E., et al. Decreased striatal dopamine transporter binding assessed with (123-I)FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology 181 2 (2005) 401-406
35. Meyer J.H., Kruger S., Wilson A.A., et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12 18 (2001) 4121-4125
36. Weintraub D., Newberg A.B., Cary M.S., et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 46 2 (2005) 227-232
37. Petrisic M.S., Augood S.J., and Bicknell R.J. Monoamine transporter gene expression in the central nervous system in diabetes mellitus. J Neurochem 68 6 (1997) 2435-2441
38. Owens W.A., Sevak R.J., Galici R., et al. Deficits in dopamine clearance and locomotion in hypoinsulinaemic rats unmask novel modulation of dopamine transporters by amphetamine. J Neurochem 94 5 (2005) 1402-1410
39. Figlewicz D.P., Brot M.D., McCall A.L., and Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 736 1-2 (1996) 54-60
40. Ichikawa H., Sakai T., Horibe Y., Kaga E., and Kawamura M. A case of chronic methyl bromide intoxication showing symmetrical lesions in the basal ganglia and brain stem on magnetic resonance imaging. Rinsho Shinkeigaku 41 7 (2001) 423-427
41. Takeda M., Tanino S., Nishinuma K., Matsubayashi T., Yamashita S., and Nishimura T. A case of hypophyseal prolactinoma with treatable delusions of dermatozoiasis. Acta Psychiat Scand 72 5 (1985) 470-475
42. Lanczik M., Hofberg K., and Brockington I.F. Delusion of infestation with post-partum onset: case report. Psychopathology 32 5 (1999) 277-280
43. Hernandez-Albujar S., Rubio G., Gopar J., Galeote G., Rey R., and Gil A. Parasitic delirium in patient with multiorganic pathology: a complex situation. An Med Interna 13 11 (1996) 549-551
44. Mendez I., Alcocer-Varela J., Parra A., et al. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin. Lupus 13 1 (2004) 45-53
45. Demaria J.E., Nagy G.M., Lerant A.A., Fekete M.I., Levenson C.W., and Freeman M.E. Dopamine transporters participate in the physiological regulation of prolactin. Endocrinology 141 1 (2000) 366-374
46. Meltzer H.Y., and Busch D. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. Psychiat Res 9 4 (1983) 285-299
47. Baker G.B., Coutts R.T., McKenna K.F., and Sherry-McKenna R.L. Insights into the mechanism of action of the MAO inhibitors phenelzine and tranylcypromide: a review. J Psychiat Neurosci 17 5 (1992) 206-214
48. Gorelick D.A., Gardner E.L., and Xi Z.X. Agents in development for the management of cocaine abuse. Drugs 64 14 (2004) 1547-1573
49. Smagin G.N., and Goeders N.E. Effects of acute and chronic ketoconazole administration on hypothalamo-pituitary-adrenal axis activity and brain corticotropin-releasing hormone. Psychoneuroendocrinology 29 10 (2004) 1223-1228
50. Olianas M.C., and Onali P. Corticotropin-releasing factor activates tyrosine hydroxylase in rat and mouse striatal homogenates. Eur J Pharmacol 150 3 (1988) 389-392
51. Izzo E., Sanna P.P., and Koob G.F. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor. Pharmacol Biochem Behav 81 4 (2005) 701-708
52. Ngai L.Y., and Herbert J. Glucocorticoid enhances the neurotoxic actions of quinolinic acid in the striatum in a cell-specific manner. J Neuroendocrinol 17 7 (2005) 424-434
53. Czyrak A., Mackowiak M., Chocyk A., Fijal K., and Wedzony K. Role of glucocorticoids in the regulation of dopaminergic neurotransmission. Pol J Pharmacol 55 5 (2003) 667-674
54. Raasch W., Muhle H., and Dominak P. Modulation of MAO activity by imidazoline and guanidine derivates. Ann NY Acad Sci 881 (1999) 313-331
55. Van den Buuse M., Zheng T.W., Walker L.L., and Denton D.A. Angiotensin-converting enzyme (ACE) interacts with dopaminergic mechanisms in the brain to modulate prepulse inhibition in mice. Neurosci Lett 380 1-2 (2005) 6-11
56. Zhou C., Xiao C., McArdle J.J., and Ye J.H. Mefloquine enhances nigral (gamma)-aminobutyric acid release via inhibition of cholinesterase. J Pharmacol Exp Ther 317 3 (2006) 1155-1160
57. Volkow N.D., Ding Y.S., Fowler J.S., et al. Dopamine transporter decrease with age. J Nucl Med 37 4 (1996) 554-559
58. Mozley P.D., Kim H.J., Gur R.C., et al. Iodine-(123i) IPT SPECT imaging of CNS dopamine transporters: non linear effect of normal aging on striatal uptake values. J Nucl Med 37 12 (1996) 1965-1970
59. Meng S.Z., Ozawa Y., Itoh M., and Takashima S. Developmental and age related changes of dopamine transporters, and dopamine D1 and D2 receptors in human basal ganglia. Brain Res 843 1-2 (1999) 136-144
60. Van Dyck C.H., Seibl J.P., Malison R.T., et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriat Psychiat 10 1 (2002) 36-46
61. Erixon-Lindroth N., Farde L., Wahlin T.B., Sovago J., Halldin C., and Backman L. The role of the striatal dopamine transporter in cognitve aging. Psychiat Res 138 1 (2005) 1-12
62. Sil'kis I.G. A role of the basal ganglia in the occurrence of visual hallucinations (a hypothetical mechanism). Zh Vyssh Nerv Deiat Im I P Pavlova 55 5 (2005) 592-607
63. Mitchell J., and Vierkant A.D. Delusions and hallucinations of cocaine abusers and paranoid schizophrenics: a comparative study. J Psychol 125 3 (1991) 301-310
64. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring evidence. Int J Neuropsychop 7 Suppl. 1 (2004) 1-5
65. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42 3 (1998) 211-221
66. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., and Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiat 46 1 (1999) 56-72
67. King B.H. Hypothesis: involvement of the serotonergic system in the clinical expression of monosymptomatic hypochondriasis. Pharmacopsychiatry 23 2 (1990) 85-89
68. Vollenweider F.X., Vontobel P., Hell D., and Leenders K.L. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with (11C) raclopride. Neuropsychopharmacology 20 5 (1999) 424-433
69. Kapur S., Agid O., Mizrahi R., and Li M. How antipsychotics work-from receptors to reality. NeuroRX 3 1 (2006) 10-21
70. Andrews E., Bellard J., and Walter-Ryan W.G. Monosymptomatic hypochondrial psychosis manifesting as delusions of infestation: case studies of treatment with haloperidol. J Clin Psychiat 47 4 (1986) 188-190
71. Damiani J.T., Flowers F.P., and Pierce D.K. Pimozide in delusions of parasitosis. J Am Acad Dermatol 22 2Pt1 (1990) 312-313
72. Lynch P.J. Delusions of parasitosis. Semin Dermatol 12 1 (1993) 39-45
73. Elmer K.B., George R.M., and Peterson K. Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol 43 4 (2000) 683-686
74. Lorenzo C.R., and Koo J. Pimozide in dermatologic practice: a comprehensive review. Am J Clin Dermatol 5 5 (2004) 339-349
75. Meehan W.J., Badreshia S., and Mackley C.L. Successful treatment of delusions of parasitosis with olanzapine. Arch Dermatol 142 3 (2006) 352-355
76. Narumoto J., Ueda H., Tsuchida H., Yamashita T., Kitabayashi Y., and Fukui K. Regional cerebral blood flow changes in a patient with delusional parasitosis before and after successful treatment with risperidone: a case report. Prog Neuropsychopharmacol Biol Pschyiat 30 4 (2006) 737-740